• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form D filed by ClearPoint Neuro Inc.

    2/5/26 8:07:29 AM ET
    $CLPT
    Medical/Dental Instruments
    Health Care
    Get the next $CLPT alert in real time by email
    SEC FORM D

    The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.
    The reader should not assume that the information is accurate and complete.

    UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    Intentional misstatements or omissions of fact constitute federal criminal violations. See 18 U.S.C. 1001.

    FORM D

    Notice of Exempt Offering of Securities
    OMB APPROVAL
    OMB Number: 3235-0076
    Estimated average burden
    hours per response: 4.00

    1. Issuer's Identity

    CIK (Filer ID Number) Previous Names
       None
    Entity Type
    0001285550
    MRI INTERVENTIONS, INC.
    SURGIVISION INC
    SURGI VISION INC
    X Corporation
       Limited Partnership
       Limited Liability Company
       General Partnership
       Business Trust
       Other (Specify)

    Name of Issuer
    ClearPoint Neuro, Inc.
    Jurisdiction of Incorporation/Organization
    DELAWARE
    Year of Incorporation/Organization
    X Over Five Years Ago
       Within Last Five Years (Specify Year)
       Yet to Be Formed

    2. Principal Place of Business and Contact Information

    Name of Issuer
    ClearPoint Neuro, Inc.
    Street Address 1 Street Address 2
    120 S. SIERRA AVENUE SUITE 100
    City State/Province/Country ZIP/PostalCode Phone Number of Issuer
    SOLANA BEACH CALIFORNIA 92075 9499006833

    3. Related Persons

    Last Name First Name Middle Name
    Burnett Joseph M.
    Street Address 1 Street Address 2
    120 S. Sierra Ave Suite 100
    City State/Province/Country ZIP/PostalCode
    Solana Beach CALIFORNIA 92075
    Relationship: X Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Fletcher R. John
    Street Address 1 Street Address 2
    120 S. Sierra Ave Suite 100
    City State/Province/Country ZIP/PostalCode
    Solana Beach CALIFORNIA 92075
    Relationship:    Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Fallon Lynnette C.
    Street Address 1 Street Address 2
    120 S. Sierra Ave Suite 100
    City State/Province/Country ZIP/PostalCode
    Solana Beach CALIFORNIA 92075
    Relationship:    Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Girin Pascal E.R.
    Street Address 1 Street Address 2
    120 S. Sierra Ave Suite 100
    City State/Province/Country ZIP/PostalCode
    Solana Beach CALIFORNIA 92075
    Relationship:    Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Johnson B. Kristine
    Street Address 1 Street Address 2
    120 S. Sierra Ave Suite 100
    City State/Province/Country ZIP/PostalCode
    Solana Beach CALIFORNIA 92075
    Relationship:    Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Klein Matthew B.
    Street Address 1 Street Address 2
    120 S. Sierra Ave Suite 100
    City State/Province/Country ZIP/PostalCode
    Solana Beach CALIFORNIA 92075
    Relationship:    Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Liau Linda M.
    Street Address 1 Street Address 2
    120 S. Sierra Ave Suite 100
    City State/Province/Country ZIP/PostalCode
    Solana Beach CALIFORNIA 92075
    Relationship:    Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Richards Timothy T.
    Street Address 1 Street Address 2
    120 S. Sierra Ave Suite 100
    City State/Province/Country ZIP/PostalCode
    Solana Beach CALIFORNIA 92075
    Relationship:    Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    D'Alessandro Danilo
    Street Address 1 Street Address 2
    120 S. Sierra Ave Suite 100
    City State/Province/Country ZIP/PostalCode
    Solana Beach CALIFORNIA 92075
    Relationship: X Executive Officer    Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Stigall Jeremy L.
    Street Address 1 Street Address 2
    120 S. Sierra Ave Suite 100
    City State/Province/Country ZIP/PostalCode
    Solana Beach CALIFORNIA 92075
    Relationship: X Executive Officer    Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Sabra Mazin
    Street Address 1 Street Address 2
    120 S. Sierra Ave Suite 100
    City State/Province/Country ZIP/PostalCode
    Solana Beach CALIFORNIA 92075
    Relationship: X Executive Officer    Director    Promoter

    Clarification of Response (if Necessary):


    4. Industry Group

       Agriculture
    Banking & Financial Services
       Commercial Banking
       Insurance
       Investing
       Investment Banking
       Pooled Investment Fund
    Is the issuer registered as
    an investment company under
    the Investment Company
    Act of 1940?
       Yes    No
       Other Banking & Financial Services
       Business Services
    Energy
       Coal Mining
       Electric Utilities
       Energy Conservation
       Environmental Services
       Oil & Gas
       Other Energy
    Health Care
    X Biotechnology
       Health Insurance
       Hospitals & Physicians
       Pharmaceuticals
       Other Health Care
       Manufacturing
    Real Estate
       Commercial
       Construction
       REITS & Finance
       Residential
       Other Real Estate
      
    Retailing
      
    Restaurants
    Technology
       Computers
       Telecommunications
       Other Technology
    Travel
       Airlines & Airports
       Lodging & Conventions
       Tourism & Travel Services
       Other Travel
      
    Other

    5. Issuer Size

    Revenue Range OR Aggregate Net Asset Value Range
       No Revenues    No Aggregate Net Asset Value
       $1 - $1,000,000    $1 - $5,000,000
       $1,000,001 - $5,000,000    $5,000,001 - $25,000,000
       $5,000,001 - $25,000,000    $25,000,001 - $50,000,000
       $25,000,001 - $100,000,000    $50,000,001 - $100,000,000
       Over $100,000,000    Over $100,000,000
    X Decline to Disclose    Decline to Disclose
       Not Applicable    Not Applicable

    6. Federal Exemption(s) and Exclusion(s) Claimed (select all that apply)

       Rule 504(b)(1) (not (i), (ii) or (iii))
       Rule 504 (b)(1)(i)
       Rule 504 (b)(1)(ii)
       Rule 504 (b)(1)(iii)
    X Rule 506(b)
       Rule 506(c)
       Securities Act Section 4(a)(5)
       Investment Company Act Section 3(c)
       Section 3(c)(1)    Section 3(c)(9)  
       Section 3(c)(2)    Section 3(c)(10)
       Section 3(c)(3)    Section 3(c)(11)
       Section 3(c)(4)    Section 3(c)(12)
       Section 3(c)(5)    Section 3(c)(13)
       Section 3(c)(6)    Section 3(c)(14)
       Section 3(c)(7)

    7. Type of Filing

    X New Notice Date of First Sale 2025-11-20    First Sale Yet to Occur
       Amendment

    8. Duration of Offering

    Does the Issuer intend this offering to last more than one year?
       Yes X No

    9. Type(s) of Securities Offered (select all that apply)

    X Equity    Pooled Investment Fund Interests
       Debt    Tenant-in-Common Securities
       Option, Warrant or Other Right to Acquire Another Security    Mineral Property Securities
       Security to be Acquired Upon Exercise of Option, Warrant or Other Right to Acquire Security    Other (describe)

    10. Business Combination Transaction

    Is this offering being made in connection with a business combination transaction, such as a merger, acquisition or exchange offer?
    X Yes    No

    Clarification of Response (if Necessary):

    11. Minimum Investment

    Minimum investment accepted from any outside investor $0 USD

    12. Sales Compensation

    Recipient
    Recipient CRD Number X None
    (Associated) Broker or Dealer X None
    (Associated) Broker or Dealer CRD Number X None
    Street Address 1 Street Address 2
    City State/Province/Country ZIP/Postal Code
    State(s) of Solicitation (select all that apply)
    Check “All States” or check individual States
       All States
       Foreign/non-US

    13. Offering and Sales Amounts

    Total Offering Amount $17,892,698 USD
    or    Indefinite
    Total Amount Sold $17,892,698 USD
    Total Remaining to be Sold $0 USD
    or    Indefinite

    Clarification of Response (if Necessary):

    Calculated based on closing price of common stock on closing date of merger. Includes up to 205,000 shares of common stock that may be cancelled to satisfy obligations of former equityholders of IRRAS Holdings, Inc. under merger agreement.

    14. Investors

      
    Select if securities in the offering have been or may be sold to persons who do not qualify as accredited investors, and enter the number of such non-accredited investors who already have invested in the offering.
    Regardless of whether securities in the offering have been or may be sold to persons who do not qualify as accredited investors, enter the total number of investors who already have invested in the offering:
    46

    15. Sales Commissions & Finder's Fees Expenses

    Provide separately the amounts of sales commissions and finders fees expenses, if any. If the amount of an expenditure is not known, provide an estimate and check the box next to the amount.

    Sales Commissions $0 USD
       Estimate
    Finders' Fees $0 USD
       Estimate

    Clarification of Response (if Necessary):

    16. Use of Proceeds

    Provide the amount of the gross proceeds of the offering that has been or is proposed to be used for payments to any of the persons required to be named as executive officers, directors or promoters in response to Item 3 above. If the amount is unknown, provide an estimate and check the box next to the amount.

    $0 USD
       Estimate

    Clarification of Response (if Necessary):

    Signature and Submission

    Please verify the information you have entered and review the Terms of Submission below before signing and clicking SUBMIT below to file this notice.

    Terms of Submission

    In submitting this notice, each issuer named above is:
    • Notifying the SEC and/or each State in which this notice is filed of the offering of securities described and undertaking to furnish them, upon written request, in the accordance with applicable law, the information furnished to offerees.*
    • Irrevocably appointing each of the Secretary of the SEC and, the Securities Administrator or other legally designated officer of the State in which the issuer maintains its principal place of business and any State in which this notice is filed, as its agents for service of process, and agreeing that these persons may accept service on its behalf, of any notice, process or pleading, and further agreeing that such service may be made by registered or certified mail, in any Federal or state action, administrative proceeding, or arbitration brought against the issuer in any place subject to the jurisdiction of the United States, if the action, proceeding or arbitration (a) arises out of any activity in connection with the offering of securities that is the subject of this notice, and (b) is founded, directly or indirectly, upon the provisions of:  (i) the Securities Act of 1933, the Securities Exchange Act of 1934, the Trust Indenture Act of 1939, the Investment Company Act of 1940, or the Investment Advisers Act of 1940, or any rule or regulation under any of these statutes, or (ii) the laws of the State in which the issuer maintains its principal place of business or any State in which this notice is filed.
    • Certifying that, if the issuer is claiming a Regulation D exemption for the offering, the issuer is not disqualified from relying on Rule 504 or Rule 506 for one of the reasons stated in Rule 504(b)(3) or Rule 506(d).

    Each Issuer identified above has read this notice, knows the contents to be true, and has duly caused this notice to be signed on its behalf by the undersigned duly authorized person.

    For signature, type in the signer's name or other letters or characters adopted or authorized as the signer's signature.

    Issuer Signature Name of Signer Title Date
    ClearPoint Neuro, Inc. /s/ Danilo D'Alessandro Danilo D'Alessandro Chief Financial Officer 2026-02-05

    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

    * This undertaking does not affect any limits Section 102(a) of the National Securities Markets Improvement Act of 1996 ("NSMIA") [Pub. L. No. 104-290, 110 Stat. 3416 (Oct. 11, 1996)] imposes on the ability of States to require information. As a result, if the securities that are the subject of this Form D are "covered securities" for purposes of NSMIA, whether in all instances or due to the nature of the offering that is the subject of this Form D, States cannot routinely require offering materials under this undertaking or otherwise and can require offering materials only to the extent NSMIA permits them to do so under NSMIA's preservation of their anti-fraud authority.


    Get the next $CLPT alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CLPT

    DatePrice TargetRatingAnalyst
    7/25/2024$10.00Buy
    B. Riley Securities
    10/24/2023$8.00Buy
    Stifel
    2/16/2023$14.00Buy
    B. Riley Securities
    4/5/2022$15.00Buy
    B. Riley Securities
    More analyst ratings

    $CLPT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CEO and President Burnett Joseph sold $45,823 worth of shares (2,943 units at $15.57) (SEC Form 4)

    4 - ClearPoint Neuro, Inc. (0001285550) (Issuer)

    1/27/26 4:27:46 PM ET
    $CLPT
    Medical/Dental Instruments
    Health Care

    CEO and President Burnett Joseph sold $322,400 worth of shares (20,000 units at $16.12) and exercised 20,000 shares at a strike of $2.50 (SEC Form 4)

    4 - ClearPoint Neuro, Inc. (0001285550) (Issuer)

    1/13/26 5:00:03 PM ET
    $CLPT
    Medical/Dental Instruments
    Health Care

    Chief Business Officer Stigall L. Jeremy was granted 1 shares, increasing direct ownership by 0.00% to 72,356 units (SEC Form 4)

    4 - ClearPoint Neuro, Inc. (0001285550) (Issuer)

    1/5/26 6:57:18 PM ET
    $CLPT
    Medical/Dental Instruments
    Health Care

    $CLPT
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    November 14, 2024 - FDA Approves First Gene Therapy for Treatment of Aromatic L-amino Acid Decarboxylase Deficiency

    For Immediate Release: November 14, 2024 The U.S. Food and Drug Administration approved Kebilidi (eladocagene exuparvovec-tneq), an adeno-associated virus vector-based gene therapy indicated for the treatment of adult and pediatric patients with aromatic L-amino acid decarboxylase (AADC) deficiency. Kebilidi is the first FDA-approved gene therapy for treatment of AADC deficiency. “Clinical advancements in the f

    11/14/24 8:50:18 AM ET
    $CLPT
    $PTCT
    Medical/Dental Instruments
    Health Care
    Biotechnology: Pharmaceutical Preparations

    $CLPT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    ClearPoint Neuro Announces FDA De Novo Marketing Authorization of SmartFlow Cannula for Direct Delivery of Gene Therapy to the Brain

    Only Device Approved to Deliver First Disease-Modifying Treatment for AADC Deficiency in the United StatesSOLANA BEACH, CA / ACCESSWIRE / November 13, 2024 / ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global therapy-enabling platform company providing navigation and delivery to the brain, today announced the U.S. Food and Drug Administration (FDA) has granted marketing authorization for the SmartFlow Neuro Cannula using the De Novo pathway. The SmartFlow Neuro Cannula is intended for intraputaminal administration of PTC Therapeutics' gene therapy KEBILIDI™ (eladocagene exuparvovec-tneq) for the treatment of aromatic L-amino acid decarboxylase (AADC) deficiency. This signifies th

    11/13/24 1:20:00 PM ET
    $CLPT
    Medical/Dental Instruments
    Health Care

    ClearPoint Neuro Reports Third Quarter 2024 Results

    Achieved Record Revenue and Growth of 41%; Operational Cash Burn Reduced to $1.2 Million SOLANA BEACH, CA / ACCESSWIRE / November 7, 2024 / ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced financial results for its third quarter ended September 30, 2024.Third Quarter HighlightsReported quarterly revenue of $8.1 million, a 41% year-over-year increase;Accelerated growth of SmartFrame OR™ platform and ClearPoint Prism® Laser Therapy System, contributing to record navigation and device revenue of $2.9 million, a 53% year-over-year increase;Overall product revenue, inc

    11/7/24 4:05:00 PM ET
    $CLPT
    Medical/Dental Instruments
    Health Care

    ClearPoint Neuro to Participate in Multiple Global Healthcare Conferences in the Fourth Quarter of 2024

    President and CEO Joe Burnett Interview Highlighted on Bloomberg Intelligence Vanguards of Healthcare Podcast TodaySOLANA BEACH, CA / ACCESSWIRE / October 31, 2024 / ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced participation in multiple investor conferences and interview formats including Bloomberg Intelligence Vanguards of Healthcare Podcast series published today. The link to the interview published this morning on Bloomberg can be found HERE.Healthcare Conferences with Participation of ClearPoint Neuro Management Include:UBS Global Healthcare Conference in

    10/31/24 4:05:00 PM ET
    $CLPT
    Medical/Dental Instruments
    Health Care

    $CLPT
    SEC Filings

    View All

    Amendment: ClearPoint Neuro Inc. filed SEC Form 8-K: Financial Statements and Exhibits

    8-K/A - ClearPoint Neuro, Inc. (0001285550) (Filer)

    2/5/26 4:25:56 PM ET
    $CLPT
    Medical/Dental Instruments
    Health Care

    SEC Form D filed by ClearPoint Neuro Inc.

    D - ClearPoint Neuro, Inc. (0001285550) (Filer)

    2/5/26 8:07:29 AM ET
    $CLPT
    Medical/Dental Instruments
    Health Care

    SEC Form EFFECT filed by ClearPoint Neuro Inc.

    EFFECT - ClearPoint Neuro, Inc. (0001285550) (Filer)

    1/23/26 12:15:30 AM ET
    $CLPT
    Medical/Dental Instruments
    Health Care

    $CLPT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    B. Riley Securities resumed coverage on ClearPoint Neuro with a new price target

    B. Riley Securities resumed coverage of ClearPoint Neuro with a rating of Buy and set a new price target of $10.00

    7/25/24 8:27:37 AM ET
    $CLPT
    Medical/Dental Instruments
    Health Care

    Stifel initiated coverage on ClearPoint Neuro with a new price target

    Stifel initiated coverage of ClearPoint Neuro with a rating of Buy and set a new price target of $8.00

    10/24/23 6:18:03 AM ET
    $CLPT
    Medical/Dental Instruments
    Health Care

    B. Riley Securities resumed coverage on ClearPoint Neuro with a new price target

    B. Riley Securities resumed coverage of ClearPoint Neuro with a rating of Buy and set a new price target of $14.00

    2/16/23 7:44:43 AM ET
    $CLPT
    Medical/Dental Instruments
    Health Care

    $CLPT
    Leadership Updates

    Live Leadership Updates

    View All

    ClearPoint Neuro Announces Appointment of Mazin Sabra as Chief Operating Officer

    SOLANA BEACH, Calif., Sept. 20, 2022 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global therapy-enabling platform company providing navigation and delivery to the brain, today announced that Mazin Sabra will join the Company effective October 10th as Chief Operating Officer. Mr. Sabra will report directly to Joe Burnett, ClearPoint Neuro's Chief Executive Officer, and serve as a member of the Company's senior leadership team. "We are thrilled to have Mazin join our team and bring his valuable and relevant skill set into our organization," commented Joe Burnett, President and CEO at ClearPoint Neuro. "Our pharma and device partners in many ways view ClearP

    9/20/22 4:05:00 PM ET
    $CLPT
    Medical/Dental Instruments
    Health Care

    ClearPoint Neuro, Inc. Announces Appointment of Mary McNamara-Cullinane as Vice President of Regulatory Affairs

    SOLANA BEACH, Calif., Aug. 08, 2022 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global therapy-enabling platform company providing navigation and delivery to the brain, today announced that Mary McNamara-Cullinane has joined the Company as Vice President of Regulatory Affairs. Ms. McNamara-Cullinane will report directly to Joe Burnett, ClearPoint Neuro's Chief Executive Officer, and serve as a member of the Company's senior leadership team. "We are thrilled to welcome Mary to our team as we fully expect her leadership and experience in Regulatory Affairs will contribute immediately to our partners and to patients globally," commented Joe Burnett, Presiden

    8/8/22 4:05:00 PM ET
    $CLPT
    Medical/Dental Instruments
    Health Care

    ClearPoint Neuro, Inc. Announces Appointment of Lynnette C. Fallon to Board of Directors

    SOLANA BEACH, Calif., July 15, 2021 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global therapy-enabling platform company providing navigation and delivery to the brain, is pleased to announce that Lynnette C. Fallon has been appointed to the Company's Board of Directors effective immediately. Ms. Fallon will also become a member of the Company's Audit Committee. Ms. Fallon is the Executive Vice President, HR/Legal, General Counsel and Secretary of Axcelis Technologies, Inc. (NASDAQ:ACLS), a provider of equipment and service solutions for the semiconductor manufacturing industry, with locations in eight countries. Ms. Fallon has held her current position sin

    7/15/21 4:30:00 PM ET
    $CLPT
    $ACLS
    Medical/Dental Instruments
    Health Care
    Industrial Machinery/Components
    Technology

    $CLPT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by ClearPoint Neuro Inc.

    SC 13G/A - ClearPoint Neuro, Inc. (0001285550) (Subject)

    11/12/24 2:35:26 PM ET
    $CLPT
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by ClearPoint Neuro Inc.

    SC 13G/A - ClearPoint Neuro, Inc. (0001285550) (Subject)

    11/8/24 4:33:36 PM ET
    $CLPT
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by ClearPoint Neuro Inc.

    SC 13G/A - ClearPoint Neuro, Inc. (0001285550) (Subject)

    11/4/24 11:28:38 AM ET
    $CLPT
    Medical/Dental Instruments
    Health Care

    $CLPT
    Financials

    Live finance-specific insights

    View All

    ClearPoint Neuro to Announce Third Quarter 2024 Results November 7, 2024

    SOLANA BEACH, Calif., Oct. 17, 2024 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced that it will release financial results for its 2024 third quarter on Thursday, November 7th, after the market close. Investors and analysts are invited to listen to the live broadcast review of the Company's 2024 third quarter on Thursday, November 7th at 4:30 p.m. Eastern time (1:30 p.m. Pacific time) which may be accessed online here. Investors and analysts who would like to participate in the conference call via telephone may do so at (888) 428-7458, or a

    10/17/24 4:05:00 PM ET
    $CLPT
    Medical/Dental Instruments
    Health Care

    ClearPoint Neuro to Announce Second Quarter 2024 Results August 7, 2024

    SOLANA BEACH, Calif., July 17, 2024 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced that it will release financial results for its 2024 second quarter on Wednesday, August 7th, after the market close. Investors and analysts are invited to listen to the live broadcast review of the Company's 2024 second quarter on Wednesday, August 7th at 4:30 p.m. Eastern time (1:30 p.m. Pacific time) which may be accessed online here. Investors and analysts who would like to participate in the conference call via telephone may do so at (888) 428-7458, or

    7/17/24 4:05:00 PM ET
    $CLPT
    Medical/Dental Instruments
    Health Care

    ClearPoint Neuro to Announce First Quarter 2024 Results May 7, 2024

    SOLANA BEACH, Calif., April 23, 2024 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced that it will release financial results for its 2024 first quarter on Tuesday, May 7th, after the market close. Investors and analysts are invited to listen to the live broadcast review of the Company's 2024 first quarter on Tuesday, May 7th, at 4:30 p.m. Eastern time (1:30 p.m. Pacific time) which may be accessed online here. Investors and analysts who would like to participate in the conference call via telephone may do so at (877) 407-9034, or at (201

    4/23/24 4:05:00 PM ET
    $CLPT
    Medical/Dental Instruments
    Health Care